FR2425859A1 - Medicament ayant une action d'inhibition sur les prostaglandine-synthetases - Google Patents

Medicament ayant une action d'inhibition sur les prostaglandine-synthetases

Info

Publication number
FR2425859A1
FR2425859A1 FR7836823A FR7836823A FR2425859A1 FR 2425859 A1 FR2425859 A1 FR 2425859A1 FR 7836823 A FR7836823 A FR 7836823A FR 7836823 A FR7836823 A FR 7836823A FR 2425859 A1 FR2425859 A1 FR 2425859A1
Authority
FR
France
Prior art keywords
prostaglandins
synthetases
medicinal product
esters
inhibiting action
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7836823A
Other languages
English (en)
Other versions
FR2425859B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roecar Holdings NV
Original Assignee
Roecar Holdings NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roecar Holdings NV filed Critical Roecar Holdings NV
Publication of FR2425859A1 publication Critical patent/FR2425859A1/fr
Application granted granted Critical
Publication of FR2425859B1 publication Critical patent/FR2425859B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Médicament ayant une action d'inhibition sur les prostaglandines synthétases, caractérisé par le fait qu'il renferme des glucosides du stérol et/ou leurs esters et/ou des glucosides de spirocétal stéroïdes et/ou leurs esters. La biosynthèse des prostaglandines est réalisée à partir des phospholipides des membranes qui sont transformées en acides arachidoniques puis en endoperoxydes de prostaglandines, enfin en prostaglandines. Ces médicaments conviennent pour le traitement des maladies dans lesquelles le taux des prostaglandines E 2 et F2 alpha doit être diminué, telles que tumeurs du conduit gastro-intestinal, troubles endocriniens, hypertrophie de la prostate, maladies cardiaques, troubles de tension artérielle, états oedémateux, maladies vasculaires, arthrites, rhumatismes et allergies.
FR7836823A 1977-12-31 1978-12-29 Medicament ayant une action d'inhibition sur les prostaglandine-synthetases Granted FR2425859A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19772759171 DE2759171A1 (de) 1977-12-31 1977-12-31 Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor

Publications (2)

Publication Number Publication Date
FR2425859A1 true FR2425859A1 (fr) 1979-12-14
FR2425859B1 FR2425859B1 (fr) 1983-04-08

Family

ID=6027873

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7836823A Granted FR2425859A1 (fr) 1977-12-31 1978-12-29 Medicament ayant une action d'inhibition sur les prostaglandine-synthetases

Country Status (19)

Country Link
JP (1) JPS54101436A (fr)
AR (1) AR223334A1 (fr)
AU (1) AU516933B2 (fr)
BE (1) BE873222A (fr)
CA (1) CA1113006A (fr)
CH (1) CH637829A5 (fr)
DE (1) DE2759171A1 (fr)
DK (1) DK587778A (fr)
ES (1) ES476443A1 (fr)
FR (1) FR2425859A1 (fr)
GB (1) GB2039217B (fr)
IL (1) IL56345A (fr)
IT (1) IT1109336B (fr)
LU (1) LU80739A1 (fr)
NL (1) NL7812656A (fr)
NZ (1) NZ189297A (fr)
PT (1) PT69012A (fr)
SE (1) SE466683B (fr)
ZA (1) ZA787399B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430233A1 (fr) * 1978-07-05 1980-02-01 Roecar Holdings Nv Medicaments du groupe des spirocetalines
EP0159431A2 (fr) * 1984-04-20 1985-10-30 Medical Research Foundation Of Oregon Cellobioside de tigogénine et son hepta-acétate, procédés de préparation et compositions pharmaceutiques contenant le cellobioside de tigogénine
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
WO1995000018A1 (fr) * 1993-06-21 1995-01-05 Medical Research Foundation Of Oregon Glycosides sequestrant le cholesterole inhibant son absorption intestinale

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5874619A (ja) * 1981-10-29 1983-05-06 Nippon Shinyaku Co Ltd リポソ−ム及びその製法
IE54837B1 (en) 1982-04-19 1990-02-28 Roecar Holdings Nv Extract of plants of the family of hypoxidaceae for treatment of cancer
DE3401178A1 (de) * 1984-01-14 1985-07-18 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen Verwendung von phytosterolglykosiden zur behandlung erhoehter 5(6)(alpha)-epoxicholesterolspiegel
DE3416112A1 (de) * 1984-04-30 1985-10-31 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren
DE3829643A1 (de) * 1988-09-01 1990-03-15 Roecar Holdings Nv Phyto- und zoosterole und deren derivate mit verbesserter wasserloeslichkeit
DE3829640C1 (fr) * 1988-09-01 1990-04-26 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederlaendische Antillen, Nl
DE3829641A1 (de) * 1988-09-01 1990-03-15 Roecar Holdings Nv Transdermal anwendbare pharmazeutische zubereitungen mit sterolinen und/oder spiroketalinen
US5166194A (en) * 1988-09-01 1992-11-24 Roecar Holdings Transdermally applicable pharmaceutical preparations having a pharmaceutically usable glycoside content
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE35018B1 (en) * 1970-03-18 1975-10-15 Liebenberg R W Therapeutic agent
US3966918A (en) * 1973-12-12 1976-06-29 Nippon Shinyaku Co., Ltd. Method of preparing aqueous solutions of sterol glycosides and their ester derivatives
JPS51118817A (en) * 1975-04-08 1976-10-19 Nippon Shinyaku Co Ltd A process for preparing absorbable steroid glycoside pharmaceutical

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430233A1 (fr) * 1978-07-05 1980-02-01 Roecar Holdings Nv Medicaments du groupe des spirocetalines
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
EP0159431A2 (fr) * 1984-04-20 1985-10-30 Medical Research Foundation Of Oregon Cellobioside de tigogénine et son hepta-acétate, procédés de préparation et compositions pharmaceutiques contenant le cellobioside de tigogénine
EP0159431A3 (en) * 1984-04-20 1986-01-08 Medical Research Foundation Of Oregon Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside
WO1995000018A1 (fr) * 1993-06-21 1995-01-05 Medical Research Foundation Of Oregon Glycosides sequestrant le cholesterole inhibant son absorption intestinale
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption

Also Published As

Publication number Publication date
IT7852493A0 (it) 1978-12-29
GB2039217B (en) 1982-08-04
SE7813443L (sv) 1979-07-01
LU80739A1 (de) 1980-01-22
AU4302478A (en) 1979-07-05
IL56345A (en) 1984-11-30
CH637829A5 (de) 1983-08-31
BE873222A (fr) 1979-06-29
AU516933B2 (en) 1981-07-02
IL56345A0 (en) 1979-03-12
NZ189297A (en) 1984-10-19
DK587778A (da) 1979-07-01
GB2039217A (en) 1980-08-06
CA1113006A (fr) 1981-11-24
DE2759171C2 (fr) 1990-10-25
ZA787399B (en) 1980-01-30
ES476443A1 (es) 1979-10-16
JPS54101436A (en) 1979-08-10
NL7812656A (nl) 1979-07-03
AR223334A1 (es) 1981-08-14
FR2425859B1 (fr) 1983-04-08
SE466683B (sv) 1992-03-23
PT69012A (pt) 1979-01-01
DE2759171A1 (de) 1979-07-12
IT1109336B (it) 1985-12-16

Similar Documents

Publication Publication Date Title
FR2425859A1 (fr) Medicament ayant une action d'inhibition sur les prostaglandine-synthetases
Santucci et al. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha.
Surh et al. 15-Deoxy-Δ12, 14-prostaglandin J2, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling
Stenson Role of eicosanoids as mediators of inflammation in inflammatory bowel disease
Lauritsen et al. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis.
Bugnicourt et al. Chronic renal failure alters endothelial function in cerebral circulation in mice
KR20040004652A (ko) 조효소 ｑ 및 에이코사펜타에노산（ｅｐａ）
FR2364030A1 (fr) Compositions pharmaceutiques a base d'anthocyanidines et procede pour leur preparation
JPS6038324A (ja) 脂肪酸組成物
JPH07502491A (ja) 皮膚疾患の治療に対して静脈的に投与される薬剤を調整するためのエマルジョンの使用
JPH06234644A (ja) 不飽和脂肪酸のエステルおよび該エステルを含有する組成物
DE60237363D1 (de) Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
DE69808619T2 (de) Prostaglandin-pharmazeutische-zusammensetzungen
CN104968349A (zh) 皮炎的治疗
JP2010513469A (ja) ポリ不飽和脂肪酸とアミンの新規なコンジュゲート、およびその治療的使用
ZA977686B (en) Fatty acid treatment.
US20230129151A1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
Kim et al. Nicotinamide reduces amyloid precursor protein and presenilin 1 in brain tissues of amyloid beta-tail vein injected mice
JPH0840981A (ja) エイコサペンタエノイルグリセライド
JP2001521539A (ja) 炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのイブプロフェンチオエステル（炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのアリールプロピオン酸、アリール酢酸及びサリチル酸塩のＣｏＡチオエステル）
JPH09268153A (ja) トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
US3985871A (en) Pharmaceutical heparinoidic factor-containing composition and therapeutic use thereof
US5668123A (en) Method of maintaining remission from venous ulcers with sulphasalazine and its metabolite
US5321045A (en) Method and composition for the treatment of imflammatory conditions using thiosulphinic acid derivatives

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse